Biochip array technology for new psychoactive substances detection in biological samples: Evaluation of the specificity of the Randox Evidence Investigator®.
New psychoactive substances; biochip; drugs of abuse; immunoassay; screening; Clinical Biochemistry; General Medicine
Abstract :
[en] BACKGROUND: The need to detect new psychoactive substances in biological samples is of crucial interest. In this paper, the specificity of a benchtop immunoanalyzer commercialized by Randox was evaluated on real patient samples.
METHOD: The Evidence Investigator was assessed to screen for NPS on 80 serum and urine samples coming from patients admitted to the emergency department. Targeted NPS were included in various categories such as synthetic cannabinoids, opioids and benzodiazepines. Results were compared with a chromatographic technique coupled with mass spectrometry.
RESULTS: No NPS was detected by the reference technique. Concerning immunoanalysis, some piperazines were positive, caused by the presence of medicine containing this chemical structure. Clonazepam and fentanyl derivatives were confirmed in some cases, but sometimes the positivity was explained by other opiates or benzodiazepines, which also explained two samples falsely positive for etizolam.
CONCLUSIONS: The Randox Evidence Investigator was rapid and easy to use. It can be used as a first intention but always followed by a more specific technique in order to detect false positive result.
Disciplines :
Pharmacy, pharmacology & toxicology
Author, co-author :
DEVILLE, Marine ; Centre Hospitalier Universitaire de Liège - CHU > > Service de toxicologie clinique, médicolégale, environnementale et en entreprise
Bailly, Ronald; 308984Analis, Suarlee, Belgium
Gauthier, Nicolas; 308984Analis, Suarlee, Belgium
Pitti, Pauline ; Centre Hospitalier Universitaire de Liège - CHU > > Pool assistant - biologie clinique
WACHTELAER, Audrey ; Centre Hospitalier Universitaire de Liège - CHU > > Département de pharmacie hospitalière
CHARLIER, Corinne ; Centre Hospitalier Universitaire de Liège - CHU > > Service de toxicologie clinique, médicolégale, environnementale et en entreprise
Language :
English
Title :
Biochip array technology for new psychoactive substances detection in biological samples: Evaluation of the specificity of the Randox Evidence Investigator®.
https://www.unodc.org/LSS/Page/NPS (accessed 28 April 2020).
United Nations Office on Drugs and Crime. World Drug Report. Sales No. E.20.XI.6. United Nations publication. Booklet 4: Cross-Cutting issues: evolving trends and new challenges, 2020.
https://www.unodc.org/LSS/Page/NPS/pharmacology (accessed 28 April 2020).
Tait RJ Caldicott D Mountain D, et al. A systematic review of adverse event arising from the use of synthetic cannabinoids and their associated treatment. Clin Toxicol 2016; 54(1): 1–3.
Mas-Morey PP Visser MHM Winkelmolen L, et al. Clinical toxicology and management of intoxications with synthetic cathinones (“Bath Salts”). J Pharm Pract 2012; 26(4): 353–357.
Wills B Erickson T. Psychoactive phenetylamine, piperazine, and pyrrolidinophenone derivatives. In: Barceloux DG (ed) Medical Toxicology of Drug Abuse: Synthesized Chemicals and Psychoactive Plants. Hoboken: Wiley, 2012.
Araújo A Carvalho M de Lourdes Bastos M, et al. The hallucinogenic world of tryptamines: an updated review. Arch Toxicol 2015; 89: 1151–1173.
Kuczyńska K Grzonkowski P Kacprzak Ł, et al. Abuse of fentanyl: an emerging problem to face. Forensic Sci 2018; 289: 207–214.
Carpenter JE Murray BP Dunkley C, et al. Designer benzodiazepines: a report of exposures recorded in the National Poison Data System, 2014–2017. Clin Toxicol 2019; 57(4): 282–286.
Graziano S Anzillotti L Mannocchi G, et al. Screening methods for rapid determination of new psychoactive substances (NPS) in conventional and non-conventional biological matrices. J Pharm Biomed Anal 2019; 163: 170–179.
Simao A Antunez M Marques H, et al. Recent bionalytical methods for the determination of new psychoactive substances in biological specimens. Bioanalysis 2020; 12(21): 1557–1595.
Smith J Sutcliffe OB Banks CE. An overview of recent developments in the analytical detection of new psychoactive substances (NPSs). Analyst 2015; 140: 4932–4948.
Wagmann L Maurer HH. Bioanalytical methods for new psychoactive substances. In: Maurer H Brandt SS (eds), New Psychoactive Substances: Pharmacology, Clinical, Forensic and Analytical Toxicology 2018; Cham, Switzerland: Springer, pp. 413–439.
Meyer MR Maurer HH. LC coupled to low- and high-resolution mass spectrometry for new psychoactive substance screening in biological matrices – where do we stand today? Anal Chim Acta 2016; 927: 13–20.
https://www.randoxtoxicology.com/biochip/(accessed 1st July 2021).
Taylor AM. Quantitative LC-MS/MS Combining Confident Identification with Scheduled MRM™, Fast Polarity Switching, UHPLC Time Scales. Technical Note (2012), Sciex. Concord, ON, Canada.
Castaneto MS Barnes AJ Concheiro M, et al. Biochip array technology immunoassay performance and quantitative confirmation of designer piperazines for urine workplace drug testing. Anal Bioanal Chem 2015; 407: 4639–4648.
Larabi A Fabresse N Etting I, et al. Rapid and simultaneous screening of new psychoactive substances and conventional drugs of abuse – a comparative study of biochip array technology versus LC-MS/MS in whole blood and urine. TIAFT Bull 2019; 49(2): 16–22.
